PRISM BioLab Co.
Latest round
- Series C
Last raised
- Sep 2021
Total raised
- $12M
Investors
- 13
About PRISM BioLab Co.
, Ltd. is a drug discovery company that focuses on developing small molecule technologies that modulate protein-protein interactions., Ltd.8 billion in an IPO, selling 4 million shares at JPY 450 per share within the expected JPY 435-450 range, on the Tokyo Stock Exchange Growth Section., Ltd.91 billion. The PRISM Library is designed to mimic a-helix or ß-turn peptide using a unique stable scaffold with corresponding dihedral angles. These motifs are essential for protein-protein interactions within the cell, especially related to transcription and translation. Using our small molecule drug discovery technology, two clinical-stage assets for cancer and fibrosis have been developed and licensed to Japanese Pharma companies. Many early lead molecules have also been created for novel or previously non-druggable targets., Ltd. and established a new subsidiary PRISM BioLab., Ltd., Ltd. Over the years, PRISM BioLab has partnered with various companies such as Eisai, Riken, Boehringer Ingelheim, Inveni AI, Merck and Servier.
Who invested in PRISM BioLab Co.
13 investors across 2 rounds
See all investors in PRISM BioLab Co.
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about PRISM BioLab Co.
Who invested in PRISM BioLab Co.?
PRISM BioLab Co. has 13 investors on record across 2 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has PRISM BioLab Co. raised?
PRISM BioLab Co. has raised 2 venture rounds. Sign up free to see how much each round raised and the total.
When did PRISM BioLab Co. last raise money?
PRISM BioLab Co.'s most recent round on record is a Series C, in Sep 2021.
What does PRISM BioLab Co. do?
PRISM BioLab Co. is a biotechnology company.
Where is PRISM BioLab Co. headquartered?
PRISM BioLab Co. is headquartered in Fujisawa-shi, Japan.
Which VCs invest in companies like PRISM BioLab Co.?
Among active investors with capital left to deploy, Shanghai State-owned Capital Investment Leading Fund, Hui Hua Fund, Yufu Capital and ICBC Capital Management back biotechnology companies at PRISM BioLab Co.'s stage. Their profiles are linked below.
VCs backing biotechnology startups at Series C
Raising like PRISM BioLab Co.? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.